Trials / Completed
CompletedNCT05366322
A Study to Compare mRNA-1273 Versus BNT162b2 COVID-19 Vaccines Among Immunocompromised Adults
Real-world Comparative Effectiveness of the mRNA-1273 Vaccine vs. BNT162b2 Vaccine Among Immunocompromised Adults in the United States
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 124,879 (actual)
- Sponsor
- ModernaTX, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this study is to compare real-world effectiveness of the mRNA-1273 vaccine versus the BNT162b2 vaccine on medically attended COVID-19 and COVID-19 hospitalizations among fully vaccinated immunocompromise participants.
Detailed description
This observational retrospective comparative effectiveness cohort study will use the HealthVerity aggregated medical and pharmacy claims database. HealthVerity data elements include provider-submitted claims, adjudicated insurance claims, and pharmacy billing manager claims submissions. Hospitalizations are included in the data at a summary level.
Conditions
Timeline
- Start date
- 2021-09-10
- Primary completion
- 2022-02-04
- Completion
- 2022-03-21
- First posted
- 2022-05-09
- Last updated
- 2022-05-09
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT05366322. Inclusion in this directory is not an endorsement.